Pulmonary heart disease, medically termed cor pulmonale, manifests as a condition marked by the enlargement and impaired function of the right ventricle of the heart. Unlike diseases originating in the left side of the heart, pulmonary heart disease is primarily driven by elevated pressure in the pulmonary arteries. These vessels play a vital role in transporting blood from the heart to the lungs for oxygenation. The genesis of pulmonary heart disease often lies in prolonged instances of heightened blood pressure within the pulmonary arteries. This heightened pressure is frequently a consequence of underlying chronic respiratory ailments such as chronic obstructive pulmonary disease (COPD), pulmonary hypertension, and various interstitial lung diseases. The persistent strain on the pulmonary circulation prompts the right ventricle to intensify its pumping efforts, leading to enlargement and, potentially, eventual failure.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States